Biotech IPOs: Will There Be A March Miracle?
This article was originally published in Scrip
Biotechnology stocks have been in a freefall since the start of 2016, keeping firms with plans for initial public offerings on the sidelines. But with values up 5% since the start of this month, will IPO hopefuls take advantage of a Miracle March or will drug pricing concerns again push share prices lower?
Register for our free email digests: